NCT00006352已完成3 期
The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG
European Organisation for Research and Treatment of Cancer - EORTC1 个研究点 分布在 1 个国家目标入组 453 人开始时间: 1999年9月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 453
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. BCG may activate the immune system to kill tumor cells. Combining monoclonal antibody therapy with BCG may kill more tumor cells. It is not yet known if monoclonal antibody therapy plus BCG is an effective treatment for limited-stage small cell lung cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of monoclonal antibody therapy plus BCG in treating patients who have limited-stage small cell lung cancer.
详细描述
OBJECTIVES:
- Determine the impact of vaccination with adjuvant BCG and monoclonal antibody BEC2 on the survival of patients with limited stage small cell lung cancer.
- Determine the progression free survival in these patients after receiving this treatment regimen.
- Determine the safety of this treatment regimen in these patients.
- Assess the quality of life in these patients treated with this regimen.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, Karnofsky performance status (60-70% vs 80-100%), and response to first line combined modality treatment (complete remission vs partial remission). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive vaccination with BCG and monoclonal antibody BEC2 intradermally on day 1 of weeks 0, 2, 4, 6, and 10 in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive no further therapy. Quality of life is assessed at baseline; at weeks 6, 12, and 24; and every 6 months thereafter until disease progression.
Patients are followed at 6 months, and then every 3 months thereafter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed limited stage small cell lung cancer (SCLC)
- •Completed first line combination treatment consisting of at least a 2 drug chemotherapy regimen (4 to 6 courses) and a chest radiotherapy regimen
- •Must have achieved clinical response (complete or partial) with no evidence of progression or relapse
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Karnofsky 60-100%
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •WBC greater than 3,000/mm^3
- •Platelet count greater than 100,000/mm^3
- •AST less than 1.5 times upper limit of normal
- •No hepatitis B
- •Not specified
- •No history of tuberculosis
- •Purified Protein Derivative negative to at least 5 IU
- •HIV negative
- •No severe active infection
- •No active infections requiring systemic antibiotics, antiviral, or antifungal treatments
- •No serious unstable chronic illness
- •No other prior malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanomatous skin cancer
- •No psychological, familial, sociological, or geographical condition that would preclude study
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •At least 4 weeks since prior immunotherapy
- •No prior therapy with mouse proteins
- •No other concurrent immunotherapy before first disease progression
- •Chemotherapy:
- •See Disease Characteristics
- •No concurrent chemotherapy before first disease progression
- •Endocrine therapy:
- •No concurrent systemic or chronic corticosteroids
- •Radiotherapy:
- •See Disease Characteristics
- •No prior radiation to spleen
- •No concurrent radiotherapy before first disease progression
- •No prior surgery for SCLC
- •No prior splenectomy
- •At least 4 weeks since prior combination therapy
- •No prior second line therapy for SCLC
- •At least 4 weeks since other prior investigational agent
- •No concurrent systemic antihistamines or nonsteroidal antiinflammatory drugs
- •No concurrent immunosuppressant therapy before first disease progression
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and ChemotherapyPrimary Peritoneal Cavity CancerOvarian CancerNCT00004115Jonsson Comprehensive Cancer Center
已完成
1 期
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone MetastasesHypercalcemia of MalignancyMetastatic CancerPainBreast CancerNCT00060138Chugai Pharmaceutical
终止
1 期
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaLymphomaNCT00033423University of Alabama at Birmingham18
已完成
2 期
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney CancerStage IV Renal Cell CancerRecurrent Renal Cell CancerNCT00019539National Cancer Institute (NCI)
Unknown
2 期
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and ChemotherapyPrimary Peritoneal Cavity CancerFallopian Tube CancerOvarian CancerNCT00003634AltaRex400